A retrospective analysis of pharmacokinetic/pharmacodynamic indices as indicators of the clinical efficacy of ciprofloxacin

被引:20
|
作者
Sánchez-Recio, MM [1 ]
Colino, CI [1 ]
Sánchez-Navarro, A [1 ]
机构
[1] Univ Salamanca, Fac Farm, Dept Farm & Tecnol Farmaceut, E-37007 Salamanca, Spain
关键词
D O I
10.1093/jac/45.3.321
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
A retrospective analysis of the relationship between estimated pharmacokinetic/pharmacodynamic indices and the reported efficacy of ciprofloxacin has been carried out using different correlation models. C-max(SS)/MIC, T-SS > MIC, (AUC(SS))/MIC and AUIC(SS) were calculated for each clinical case included in the study, from simulated plasma level curves corresponding to the dosage regimen administered. A univariate correlation analysis was performed considering efficacy (%) as the dependent variable and indices as the independent variables according to linear and non-linear pharmacokinetic-pharmacodynamic models (PK-PD models),The results prove that log-transformation of the independent variable improves the data fitting to linear model. The four estimated indices show a log-linear relationship with outcome, T-SS > MIC and AUIC(SS) being the parameters best correlated with percentage efficacy. The E-max model with intrinsic response is an additional correlation strategy for T-SS > MIG, leading to estimated values of E-max and E-0 of 100.34 +/- 25.09% and 24.40 +/- 11.7%, respectively. The wide range of bacteria responsible for the infections considered, including Gram-positive pathogens such as staphylococci, might explain the good correlation between T-SS > MIC and percentage efficacy found for ciprofloxacin in this study.
引用
收藏
页码:321 / 328
页数:8
相关论文
共 50 条
  • [21] Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat
    Reiner Frey
    Corina Becker
    Soundos Saleh
    Sigrun Unger
    Dorina van der Mey
    Wolfgang Mück
    Clinical Pharmacokinetics, 2018, 57 : 647 - 661
  • [22] Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review
    Byon, Wonkyung
    Garonzik, Samira
    Boyd, Rebecca A.
    Frost, Charles E.
    CLINICAL PHARMACOKINETICS, 2019, 58 (10) : 1265 - 1279
  • [23] Clinical Pharmacokinetic and Pharmacodynamic Profile of Lacosamide
    Cawello, Willi
    CLINICAL PHARMACOKINETICS, 2015, 54 (09) : 901 - 914
  • [24] Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat
    Fritsch, Achim
    Meyer, Michaela
    Blaustein, Robert O.
    Trujillo, Maria E.
    Kauh, Eunkyung
    Roessig, Lothar
    Boettcher, Michael
    Becker, Corina
    CLINICAL PHARMACOKINETICS, 2024, 63 (06) : 751 - 771
  • [25] CHIRALITY - CLINICAL PHARMACOKINETIC AND PHARMACODYNAMIC CONSIDERATIONS
    LEE, EJD
    WILLIAMS, KM
    CLINICAL PHARMACOKINETICS, 1990, 18 (05) : 339 - 345
  • [26] Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban
    Wolfgang Mueck
    Jan Stampfuss
    Dagmar Kubitza
    Michael Becka
    Clinical Pharmacokinetics, 2014, 53 : 1 - 16
  • [27] Clinical Pharmacokinetic and Pharmacodynamic Profile of Lacosamide
    Willi Cawello
    Clinical Pharmacokinetics, 2015, 54 : 901 - 914
  • [28] Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review
    Wonkyung Byon
    Samira Garonzik
    Rebecca A. Boyd
    Charles E. Frost
    Clinical Pharmacokinetics, 2019, 58 : 1265 - 1279
  • [29] Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat
    Frey, Reiner
    Becker, Corina
    Saleh, Soundos
    Unger, Sigrun
    van der Mey, Dorina
    Mueck, Wolfgang
    CLINICAL PHARMACOKINETICS, 2018, 57 (06) : 647 - 661
  • [30] Clinical Pharmacokinetic and Pharmacodynamic Profile of Etoricoxib
    Jody K. Takemoto
    Jonathan K. Reynolds
    Connie M. Remsberg
    Karina R. Vega-Villa
    Neal M. Davies
    Clinical Pharmacokinetics, 2008, 47 : 703 - 720